Desmoglein Compensation Theory: An explanations for Early Appearance of Oral lesions as Compared to Skin Lesions in Pemphigus Vulgaris

  • Safia Siddiqui Department of Oral Pathology and Microbiology, Sardar Patel Post Graduate Institute of Dental & Medical Sciences, Lucknow- 226025 (U.P.)
  • Mohammad Asad Haroon Assistant Professor, Department of Dermatology, Integral Institute Medical Sciences and Research, Lucknow
  • Shamim ul Hasan Assistant Professor, Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Milia Islamia, New Delhi
  • Aeman Khalid Post Graduate Student (MD pathology), Jawaharlal Nehru Medical College, AMU, Aligarh
Keywords: Pemphigus, Desmoglein Compensation Theory, Autoimmune disorder, Blister


Pemphigus is a life-threatening autoimmune blistering disease targeting skin and mucous membranes. It is clinically characterized by flaccid blisters and erosions, while histologically shows intraepithelial acantholysis.  The disruption of desmoglein-dependent cell adhesion by autoantibodies is the basic pathophysiology in blister formation of pemphigus.

The clinical and histological spectrum of pemphigus is complex and differs in various variants of pemphigus. This review offers an answer to why the splits associated with pemphigus foliaceus occur in the superficial layer of the epidermis, while those of pemphigus vulgaris occur deep in the epidermis. With the help of desmoglein compensation theory, it logically explains why oral erosions develop in patients with pemphigus vulgaris, but not in patients with pemphigus foliaceus and why some patients with pemphigus vulgaris have only oral involvement, but others have extensive lesions on both skin and mucous membranes.

Learning objective: After completing this article, readers shall be familiar with the clinical presentations, histologic findings, immunopathology  of classical pemphigus and its  variants. It discusses the  desmoglein compensation theory of pathogenesis. along with the management of pemphigus.


Download data is not yet available.


1. BOLOGNIA J L, JORIZZO J L, SCHAFFER J V. Dermatology. 3rd edition. Vol 1. Saunders Elseviers, New Delhi; 2012: 461- 473.
2. SCULLY C, CHALLACOMBE S J. PEMPHIGUS VULGARIS: Update on Etiopathogenesis, Oral Manifestations And Management. Crit Rev Oral Biol Med 2002; 13(5): 397-408.
3. RAJENDRAN R, SIVAPATHASUNDARAM. Shafer's textbook of oral pathology. New Delhi: Elsevier, 2012: 824-828.
4. BEUTNER EH, JORDON RE. Demonstration of skin antibodies in sera of Pemphigus vulgaris patients by indirect immunoflourescent staining. Proc Soc Exp Biol Med1964; 117: 505-10.
5. BECKER BA, GASPARI AA. Pemphigus vulgaris and vegetans. Dermatol Clin 1993; 11:429-453.
6. RAMIREZ-AMADOR VA, ESQUIVEL-PEDRAZA L, OROZCO-TOPETE R. Frequency of oral conditions in a dermatology clinic. Int J Dermatol 2000; 39: 501-505.
7. GROVES RW. Pemphigus: a brief review. Clinical Medicine 2009; 9 (4):371–5.
8. EVERSOLE LR. Immunopathology of oral mucosal ulcerative, desquamative and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol 1994; 77: 555-571.
9. WEINBERG MA, INSLER MS, CAMPEN RB. Mucocutaneous features of autoimmune blistering diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 517-534.
10. HARMAN KE, ALBERT S, BLACK MM. British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-37.
11. KAVALA M, ALTINTAS S, KOCATURK E, ZINDANCI I, CAN B, RUHI C, TURKOGLU Z. Ear, nose and throat involvement in patients with pemphigus vulgaris: correlation with severity, phenotype and disease activity. JEADV 2011; 25: 1324–1327.
12. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. Br J Dermatol 2001; 144(6): 1177- 1182.
13. ROBINSON ND, HASHIMOTO T, AMAGAI M, CHAN LS. The new pemphigus variants. J Am Acad Dermatol. 1999; 40: 649–671.
14. ANHALT GJ. Paraneoplastic pemphigus. Adv Dermatol 1997;12:77-96.
15. ANHALT GJ, KIM S, STANLEY JR, KORMAN NJ, JABS DA, KORY M, IZUMI H, et al. Paraneoplastic Pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Eng J Med. 1990; 323: 1729-35.
16. BEUTNER EH, CHORZELSKI TP, WILSON RM, KUMAR V, MICHEL B, HELM F, JABLONSKA S. IgA pemphigus foliaceus: report of two cases and a review of the literature. J Am Acad Dermatol 1989; 20:89-97.
17. EBIHARA T, HASHIMOTO T, IWATSUKI K,TAKIGAWA M, ANDO M, OHKAWARA A, NISHIKAWA T . Autoantigens for IgA anti-intercellular antibodies of intercellular IgA vesiculopustular dermatosis. J Invest Dermatol 1991;97:742-5.
18. AMAGAI M, KOCH P J, NISHIKAWA T, STANLEY JR. Pemphigus Vulgaris antigen (Desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol.1996; 106: 351–355.
19. AMAGAI M, HASHIMOTO T, SHIMIZU N, NISHIKAWA T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59.
20. GETSIOS S, HUEN AC, GREEN KJ. Working out the strength and flexibility of desmosomes. Nat Rev Mol Cell Biol 2004; 5: 271.
21. YOKOUCHI M, SALEH MA, KURODA K, HACHIYA T, STANLEY JR, AMAGAI M, ISHII K. Pathogenic epitopes in pemphigus unmasked by proteolysis. J Inv Dermatol 2009; 129: 2156-2166.
22. SHIRAKATA Y, AMAGAI M, HANAKAWA Y, NISHIKAWA T, HASHIMOTO K. Lack of mucosal involvement in Pemphigus Foliceous may be due to low expression of desmoglein 1. J Invest Dermatol. 1998; 110: 76-8.
23. MAHONEY MG, WANG Z, ROTHENBERGER K, KOCH PJ, AMAGAI M, STANLEY JR. Explanation for the clinical and microscopic localisation of lesions in Pemphigus foliceus and vulgaris. J Clin Invest.1999; 103: 461-8.
24. STANLEY JR, AMAGAI M. Pemphigus Bullous Impetigo and the staphylococcal scalded skin syndrome. N Engl J Med. 2006; 355: 1800-10.
25. PAYNE AS, HANAKAWA Y, AMAGAI M, STANLEY JR. Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol 2004; 16: 536.
26. JONES JCR, YOKOO KM, GOLDMAN R. Further analysis of pemphigus autoantibodies and their use in studies on the heterogeneity, structure and function of desmosomes. J Cell Biol 1986; 102: 1109.
27. AMAGAI M, TSUNODA K, ZILLIKENS D, NAGAI T, NISHIKAWA T. The clinical phenotype of pemphigus is defined by the antidesmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167.
28. DING X, AOKI V, MASCARO` JM, LOPEZ-SWIDERSKI A, DIAZ LA, FAIRLEY LA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 592.
29. NAGASAKA T, NISHIFUJI K, OTA T, WHITTOCK NV, AMAGAI M. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scaled skin syndrome. J Clin Invest. 2004; 114: 1484.
30. TSUNODA K, OTA T, AOKI M, YAMADA T, NAGAI T, NAKAGAWA T, KOYASU S et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the aminoterminal adhesive interface of desmoglein 3. J Immunol 2003; 170: 2170.
31. AMAGAI M. Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 1999; 20: 92.
32. UDEY MC, STANLEY JR. Pemphigus – diseases of antidesmosomal autoimmunity. JAMA 1999; 282: 572.
33. GRANDO SA, PITTELKOW MR, SHULTZ LD, DMOCHOWSKI M, NGUYEN VT. Pemphigus: an unfolding story. J Invest Dermatol 2001; 117: 990.
34. LANZA A, CIRILLO N, FEMIANO F, GOMBOS F. How does acantholysis occur in pemphigus vulgaris: a critical review. J Cutan Pathol 2006; 33: 401–412.
35. DURDU M, BABA M, SECKIN D. The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions, J Am Acad Dermatol. 2008; 59( 6): 2008 958-964.
36. BLANK H, BURGOON CF. Abnormal cytology of epithelial cells in pemphigus vulgaris: a diagnostic aid. J Invest Dermatol 1952; 18:213-23. .
37. GUPTA LK, SINGHI MK. Tzanck smear: a useful diagnostic tool. Indian J Dermatol Venereol Leprol 2005;71: 295-9.
38. KASPERKIEWICZ M, SCHMIDT E, ZILLIKENS D. Current therapy of the pemphigus group. Clinics in Dermatology. 2012; 30: 84–94.
39. SUNDHARAM J. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol 2006; 72:173-4.
40. TOTH GG, JONKMAN M F. Therapy of Pemphigus. Clinics in Dermatology 2001;19: 761–767.
41. HASHIMOTO T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res A 2003; Apr;295 Suppl 1:S2-11.
How to Cite
Siddiqui S, Haroon MA, Hasan S ul, Khalid A. Desmoglein Compensation Theory: An explanations for Early Appearance of Oral lesions as Compared to Skin Lesions in Pemphigus Vulgaris. Int Arch BioMed Clin Res [Internet]. 2016Sep.28 [cited 2019Dec.14];2(3):13-7. Available from: